Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer

首页> 外文期刊>Journal of international management >Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer

【24h】

Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer

机译：非小细胞肺癌和抗铂卵巢癌患者抗NAPI2B抗体 - 药物共轭寿命的抗NAPI2B抗体 - 药物缀合物Lifastuzumab Vedotin DNIB0600A

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: This phase 1 trial assessed the safety, tolerability, and preliminary antitumor activity of lifastuzumab vedotin (LIFA), an antibody-drug conjugate of anti-NaPi2b mAb (MNIB2126A) and a potent antimitotic agent (monomethyl auristatin E).

机译：目的：该第1阶段试验评估了Lifastuzumab Vedotin（LIFA）的安全性，耐受性和初步抗肿瘤活性，抗NaPi2B mAb（MNIB2126A）和有效抗杀剂（Monomethylauristatin E）的抗体 - 药物缀合物。

著录项

来源
《Journal of international management》 |2020年第2期|共9页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类管理学;
关键词

相似文献

外文文献
中文文献
专利

1. Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer [J] . Journal of international management . 2020,第2期

机译：非小细胞肺癌和抗铂卵巢癌患者抗NAPI2B抗体 - 药物共轭寿命的抗NAPI2B抗体 - 药物缀合物Lifastuzumab Vedotin DNIB0600A
2. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study [J] . Banerjee S., Oza A. M., Birrer M. J., Annals of oncology: official journal of the European Society for Medical Oncology . 2018,第4期

机译：抗NaPi2B抗体 - 药物缀合物Lifastuzumab Vedotin（DNIB0600A）与铂抗脂质糖尿病患者在随机的，开放标签，II期研究中的患者患者中相比
3. PHARMACOKINETICS OF ANTIBODY-DRUG CONJUGATE (ADC)-DNIB0600A IN A PHASE I STUDY IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER (OC)/NON-SMALL CELL LUNG CANCER (NSCLC). [J] . Xu J., Burris H. III, Gordon M., Clinical Pharmacology and Therapeutics . 2015,第S1期

机译：Ⅰ期抗铂药物卵巢癌（OC）/非小细胞肺癌（NSCLC）患者的抗药性药物结合物（ADC）-DNIB0600A的药代动力学。
4. Gene expression profiles predict survival of patients with advanced non-small cell lung cancers [C] . Harun Roslan, Hadi Jalal, Mhazir Nur Shukriyah, 2011 Fourth International Conference on Modeling, Simulation and Applied Optimization . 2011

机译：基因表达谱预测晚期非小细胞肺癌患者的生存
5. Assessing the effectiveness of palliative chemotherapy for non-small cell lung cancer: A phase IV study of patients treated at Ontario's cancer centres [D] . Harrison, Lyndsay Dawn. 2012

机译：评估姑息化疗对非小细胞肺癌的有效性：在安大略省癌症中心接受治疗的患者的IV期研究
6. Enapotamab vedotin an AXL-specific antibody-drug conjugate shows preclinical antitumor activity in non-small cell lung cancer [O] . Louise A. Koopman, Mikkel G. Terp, Gijs G. Zom, 2019

机译：Enapotamab vedotin一种AXL特异性抗体-药物结合物在非小细胞肺癌中显示出临床前抗肿瘤活性
7. Circulating tumour DNA (ctDNA) analysis in patients (pts) with non-small cell lung cancer (NSCLC) treated with telisotuzumab vedotin (teliso-v), an antibody-drug conjugate targeting c-Met [O] . R.S. Heist, M. Motwani, L. Naumovski, 2019

机译：用Telisotuzumab Vedotin（Teliso-V）处理的非小细胞肺癌（NSCLC）循环肿瘤DNA（CTDNA）分析（PTS），靶向C-Met的抗体 - 药物缀合物

Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer

摘要

著录项

相似文献

相关主题

期刊订阅